Fergus graduated from the University of Edinburgh with an MChem in 2013 and obtained his PhD in Stem Cell Research (2017) from the MRC Centre for Regenerative Medicine under the supervision of Prof. Tilo Kunath and Prof. Alison Hulme. His research focused on the development of neuroregenerative therapies and tools for the treatment of Parkinson’s Disease in collaboration with industrial sponsor UCB. He then moved to the west coast of Scotland to complete an EPSRC funded postdoc at the University of Glasgow (2018), identifying specific folding topologies of conotoxin derived peptidomimetics (Prof. Andrew Jamieson) in collaboration with Dstl. Since he joined the Burley Group in 2019, Fergus has worked on the development of transcriptional regulators for neurodegenerative diseases and new cell penetrative delivery vectors. Now he is leading the scientific development of TargoPep as Chief Scientific Officer.